BUSINESS

• JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
  May 22, 2014

• Takeda’s UC, CD Treatment Entyvio Approved in US
  May 22, 2014

• EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
  May 21, 2014

• AZ to Highlight Global Data to Push Forxiga: Primary Care Head
  May 21, 2014

• Towa Wins Japan’s 1st Approval for Viagra Generic
  May 21, 2014

• Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
  May 20, 2014

• Medipal Holdings Sets 2,253 Billion Yen Goal for FY2016 Ethical Drug Wholesaling Sales
  May 20, 2014

• Daiichi Sankyo to Revise Its Midterm Business Plan Due to Transfer of Ranbaxy
  May 20, 2014

• Sales of 25 Major Japan Drug Makers Up 10% as Top 4 Pharmas’ Offshore Revenues Flourish
  May 19, 2014

• Blopress Generic to Go on Sale after June Listing, Japan’s 1st AG to Hit Shelves Before Rivals
  May 19, 2014

• RaQualia, Kyoto University, iPS Academia Japan Announce Joint Research Agreement
  May 19, 2014

• Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
  May 19, 2014

• Olmesartan Sales Exceed 300 Billion Yen in FY2013: Daiichi Sankyo
  May 16, 2014

• Generic Makers See Softer Sales Growth in FY2013
  May 16, 2014

• Merck Deal Marks a Stride towards Top 3 in Global Ophthalmic Space: Santen Veep
  May 16, 2014

• Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
  May 16, 2014

• Nichi-Iko to Assign over 70 Sales Reps Specializing in DPC Hospitals within 2014
  May 16, 2014

• Otsuka Holdings’ Pharmaceutical Sales Top 1 Trillion Yen for First Time
  May 15, 2014

• Hisamitsu Takes Aim at 190 Billion Yen Sales in FY2018
  May 15, 2014

• Ono to Introduce Sales Reps Specializing in Oncology for Entry to Oncology Market in Japan
  May 15, 2014

ページ

• « 先頭
• ‹ Prev
• …
• 555
• 556
• 557
• 558
• 559
• 560
• 561
• 562
• 563
• …
• Next ›
• 最終 »